Article information
Full text is only aviable in PDF
REFERENCES
[1]
F Álvarez, E Bouza, JA García-Rodríguez, MA Mayer, J Mensa, E Monsó, et al.
Uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 38 (2002), pp. 81-89
[2]
F Álvarez, E Bouza, JA García-Rodríguez, E Monsó, JJ Picazo, V Sobradillo, et al.
Segundo documento de consenso sobre uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 39 (2003), pp. 274-282
[3]
NR Anthonisen, J Manfreda, PW Warren, ES Hershfield, GK Harding, NA Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[4]
S Nouira, S Marghli, M Belghith, L Besbes, S Elatrous, F Abroug.
Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.
Lancet, 358 (2001), pp. 2020-2025
[5]
F Baquero, JA García-Rodríguez, J García, L Aguilar, the Spanish Surveillance Group for Respiratory Pathogens.
Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study.
Antimicrob Agents Chemother, 43 (1999), pp. 357-359
[6]
JR Lonks, J Garau, L Gómez, M Xercavins, A Ochoa de Echaguen, IF Gareen, et al.
Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin- resistant Streptococcus pneumoniae..
Clin Infect Dis, 35 (2002), pp. 556-564
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
